[Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D003018:Clot Retraction; D004185:Disability Evaluation; D004844:Epistaxis / Q000517:prevention & control; D005164:Factor IX / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis / Q000627:therapeutic use*; D006395:Hemarthrosis / Q000517:prevention & control; D006417:Hematuria / Q000517:prevention & control; D002836:Hemophilia B / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control*; D006760:Hospitalization; D006801:Humans; D007275:Injections, Intravenous; D007902:Length of Stay; D011517:Prothrombin Time; D012574:Schools; D013916:Thrombelastography; D013925:Thromboplastin / Q000032:analysis
D005164:Factor IX; D013925:Thromboplastin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Prophylaktische Behandlung bei schwerer Hämophilie B mit einem Faktor-IX-Konzentrat